<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886468</url>
  </required_header>
  <id_info>
    <org_study_id>2016-03-CHRMT</org_study_id>
    <nct_id>NCT02886468</nct_id>
  </id_info>
  <brief_title>DEpth of EPinephrine Delivery With Auto-injectors Devices</brief_title>
  <acronym>DEEP</acronym>
  <official_title>Determinants of Muscle - Skin Distance at the Injection Site in Patients With an Indication for the Use of Epinephrine Auto- Injector Pens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional Metz-Thionville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional Metz-Thionville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.
      Although there are several causes of fatal anaphylaxis, food allergy is one of the most
      common. Epinephrine is recommended as the initial treatment of choice for anaphylaxis. A
      delay in epinephrine administration may contribute to an increased risk of death. Therefore,
      the World Allergy Organization recommends that, for the treatment of anaphylaxis, epinephrine
      solution be administered intramuscularly in the mid-anterolateral thigh.

      In France 3 auto-injector pens are available: Anapen®, Epipen® and Jext®. For weight&gt; 30 kg,
      the devices have a needle size respectively of 7.49 mm, 15.02 mm and 15.36 mm. For the
      weights between 15 and 30 kg needle size is 7.49 mm to 12.7 mm and Anapen® for Epipen® and
      Jext®.

      Several studies suggest that the needle length needle is sometim
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin-to-muscle and muscle-to-bone distance assessment, with compression, for intramuscular injection depending on needle length of the auto-injector pen.</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anaphylactic Shock</condition>
  <arm_group>
    <arm_group_label>ultrasound images</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ultrasound images of the anterolateral aspect of the mid-right thigh</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>skin ultrasound</intervention_name>
    <arm_group_label>ultrasound images</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a weight of over 30 kg at Baseline

          -  with food or an Hymenoptera venom allergy (diagnosed by skin tests or serum-specific
             IgE testing, requiring prescription epinephrine auto-injector pen according to
             European recommendations,

        Exclusion Criteria:

          -  having a skin lesion on the lateral aspect of the thigh,

          -  with a known or suspected allergy to the contact gel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sébastien LEFEVRE, MD</last_name>
    <email>s.lefevre@chr-metz-thionville.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia OUAMARA</last_name>
    <email>n.ouamara@chr-metz-thionville.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chr Metz Thionville</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia OUAMARA, M.Sc., Ing.</last_name>
      <phone>+33 3 87 55 77 52</phone>
      <email>n.ouamara@chr-metz-thionville.fr</email>
    </contact>
    <contact_backup>
      <last_name>Naoual MELLOUKI, PhD</last_name>
      <phone>+33 3 87 18 98 83</phone>
      <email>n.mellouki@chr-metz-thionville.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sébastien LEFEVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anaphylaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

